Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety, Tolerability, PK and PD Study of AZD6234 in Participants With Overweight or Obesity
jRCT2051240086Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Peptides
01
Overview
Phase 1, randomised, single-blind trial in Overweight and obesity comparing AZD6234 with Placebo (2 arms). Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Jul 2024; status: completed.
02
Drugs
lenbelintide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on jRCT2051240086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240086.